Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals
Links shared publicly online about this topic.
- 1,648total visits
Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals
Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.
View full resource at news-medical.net
Tags: Gastroenterology, HIV, AIDS, STD, Cystic Fibrosis, Kidney Disease, Pharma, News
Most Recently Shared on October 26, 2009 at 4:54 pm By:
HIV/AIDS News: Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals: Napo Pharma.. http://bit.ly/tikie
Advertisement
